SAN
DIEGO, June 4, 2024 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
that it expects to be added to the broad-market Russell 3000® Index
and the Russell 2000® Index at the conclusion of the 2024 Russell
US Indexes annual reconstitution, effective at the open of US
equity markets on Monday, July 1st,
according to a preliminary list of additions posted Friday, May 24th.
The annual Russell US Indexes reconstitution captures the 4,000
largest US stocks as of Tuesday, April
30th, ranking them by total market capitalization.
Membership in the US all-cap Russell 3000® Index, which remains in
place for one year, means automatic inclusion in the large-cap
Russell 1000® Index or small-cap Russell 2000® Index as well as the
appropriate growth and value style indexes. FTSE Russell determines
membership for its Russell indexes primarily by objective,
market-capitalization rankings, and style attributes.
"The addition of Regulus to the Russell indexes is an
achievement that underscores the forward momentum of the company as
a whole," said Jay Hagan, Chief
Executive Officer of Regulus Therapeutics. "This update is also a
reflection of the value of our pipeline, including our RGLS8429
program for the treatment of patients living with ADPKD."
Russell indexes are widely used by investment managers and
institutional investors for index funds and as benchmarks for
active investment strategies. According to the data as of the end
of December 2023, about $10.5 trillion in assets are benchmarked against
the Russell US indexes, which belong to FTSE Russell, a prominent
global index provider.
Fiona Bassett, CEO of FTSE
Russell, An LSEG Business, comments: "Russell indexes–now in their
40th year–continue to evolve to reflect the dynamic US
economy. Annual rebalancing plays a vital role in establishing
accurate benchmarks, ensuring they correctly mirror their
designated market segments and remain unbiased in terms of size and
style."
For more information on the Russell 3000® Index and
the Russell indexes reconstitution, go to the "Russell
Reconstitution" section on the FTSE Russell website.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical
company focused on the discovery and development of innovative
medicines targeting microRNAs. Regulus has leveraged its
oligonucleotide drug discovery and development expertise to develop
a pipeline complemented by a rich intellectual property estate in
the microRNA field. Regulus maintains its corporate headquarters in
San Diego, CA.
About FTSE Russell:
FTSE Russell is a leading global provider of benchmarking,
analytics, and data solutions for investors, giving them a precise
view of the market relevant to their investment process. A
comprehensive range of reliable and accurate indexes provides
investors worldwide with the tools they require to measure and
benchmark markets across asset classes, styles, or strategies.
FTSE Russell index expertise and products are used extensively
by institutional and retail investors globally. For over 30 years,
leading asset owners, asset managers, ETF providers and investment
banks have chosen FTSE Russell indexes to benchmark their
investment performance and create ETFs, structured products, and
index-based derivatives.
FTSE Russell is focused on applying the highest industry
standards in index design and governance, employing transparent
rules-based methodology informed by independent committees of
leading market participants. FTSE Russell fully embraces the IOSCO
Principles, and its Statement of Compliance has received
independent assurance. Index innovation is driven by client needs
and customer partnerships, allowing FTSE Russell to continually
enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
For more information, visit
https://www.lseg.com/en/ftse-russell.
Forward-Looking Statements
Statements contained in this presentation regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements associated with the Company's RGLS8429
program and preclinical pipeline, the expected timing for
completing clinical studies, potentially achieving therapeutic
efficacy and clinical translation for patients, the expected timing
for reporting topline data, and the timing and future occurrence of
other preclinical and clinical activities. Because such statements
are subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar
expressions are intended to identify forward-looking statements.
These forward-looking statements are based upon Regulus' current
expectations and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties, which include, without limitation, the approach we
are taking to discover and develop drugs is novel and may never
lead to marketable products, preliminary or initial results may not
be indicative of future results, preclinical and clinical studies
may not be successful, risks related to regulatory review and
approval, risks related to our reliance on third-party
collaborators and other third parties, risks related to
intellectual property, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, and the risk additional
toxicology data may be negative and our need for additional
capital. These and other risks are described in additional detail
in Regulus' filings with the Securities and Exchange Commission,
including under the "Risk Factors" heading of Regulus' most
recently filed quarterly report on Form 10-Q. All forward-looking
statements contained in this press release speak only as of the
date on which they were made. Regulus undertakes no obligation to
update such statements to reflect events that occur or
circumstances that exist after the date on which they were
made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-announces-expected-addition-to-the-russell-3000-and-russell-2000-indexes-302162634.html
SOURCE Regulus Therapeutics Inc.